Atypical activation of Gαq by the oncogenic mutation Q209P.

The causative role of G protein-couple receptor (GPCR) pathway mutations in uveal melanoma has been well established. Nearly all UMs bear an activating mutation in a GPCR pathway mediated by G proteins of the Gq/11 family, driving tumor initiation and possibly metastatic progression. Thus, targeting this pathway holds therapeutic promise for managing UM. However, direct targeting of oncogenic Gαq/11 mutants, present in ~90% of UMs, is complicated by the belief that these mutants structurally resemble active Gαq/11 wild-type. This notion is solidly founded on previous studies characterizing Gα mutants in which a conserved catalytic glutamine (Q209 in Gαq) is replaced by leucine, which leads to GTPase function deficiency and constitutive activation. While Q209L accounts for approximately half of GNAQ mutations in UM, Q209P is as frequent as Q209L and also promotes oncogenesis, but has not been characterized at the molecular level. Here we characterized the biochemical and signaling properties of Gαq Q209P, and found that it is also GTPase-deficient and activates downstream signaling as efficiently as Gαq Q209L. However, Gαq Q209P had distinct molecular and functional features, including in the switch II region of Gαq Q209P, which adopted a conformation different from that of Gαq Q209L or active wild-type Gαq, resulting in altered binding to effectors, Gβγ and Regulators of G-protein signaling (RGS) proteins. Our findings reveal that the molecular properties of Gαq Q209P are fundamentally different from those in other active Gαq proteins and could be leveraged as a specific vulnerability for the ~20% of UMs bearing this mutation.